AC Immune SA (ACIU)
AC Immune SA (ACIU) Stock Price, Analysis & Data
| Bid | 1.6 |
| Market Cap | 253.42M |
| Revenue (ttm) | 17.51M |
| Net Income (ttm) | -43.16M |
| Beta | 1.57 |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | n/a |
| Forward PE | 4.09 |
| P/B (ttm) | 5.76 |
| P/S (ttm) | 14.14 |
| Earnings Date | Nov 4, 2026 |
| Ask | 2.9 |
| Volume | 131,221 |
| Avg. Volume (20D) | 259,788 |
| Open | 2.58 |
| Previous Close | 2.57 |
| Day's Range | 2.43 - 2.58 |
| 52-Week Range | 2.03 - 4.00 |
| Analyst | Strong Buy |
| Price Target | 8.44 (238.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative dis...
Financial Performance
In 2025, AC Immune SA's revenue was 3.57M, a decrease of -86.92% compared to the previous year's 27.31M. Earnings were -70.45M, an increase of 38.36%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for ACIU stock is "Strong Buy". The 12-month stock price forecast is 8.44, which is upside of 238.96% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
